Abstract
An estimated 15.5 million people have an opioid use disorder across the globe resulting in tremendous morbidity and mortality. In the United States, the toll of untreated opioid use disorder has led to an epidemic of overdose deaths resulting in a decline in life expectancy over the past three years. Much of the focus in responding to the opioid overdose crisis has been on supply reduction or expanding the existing treatment system. Supply reduction or expansion of the existing treatment system may not target the needs of people who are actively using drugs and at highest risk of harm or death. In contrast, harm reduction offers a practical approach which focuses on reducing negative consequences and improving the lives and health of people who use opioids. Harm reduction is a philosophy and an approach which focuses on minimizing harm and promoting health, rather than necessarily reducing drug use. A broad range of harm reduction interventions has been studied and found to be successful, including syringe service programs, supervised consumptions sites, naloxone distribution, safer use education, low-threshold treatment models, and prescription heroin programs. Many components of these specific interventions can be incorporated into clinical practice. In addition, the general principles of harm reduction can inform a patient-centered care model both within addiction treatment programs and general medical settings to improve the health of and clinical outcomes for patients. This approach embraces the notion that people who continue to use drugs deserve equitable and dignified care delivered with respect and without judgment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N, Vos T. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction. 2014;109(8):1320–33.
United Nations Office on Drugs and Crime (2017). World drug report 2017. Available online at: https://www.unodc.org/wdr2017/field/WDR_2017_presentation_lauch_version.pdf. Accessed 26 June 2018.
Bernstein L. U.S. life expectancy declines again, a dismal trend not seen since World War I. Washington Post. November 28, 2018. Available online at https://www.washingtonpost.com/national/health-science/us-life-expectancy-declines-again-a-dismal-trend-not-seen-since-worldwar-i/2018/11/28/ae58bc8c-f28c-11e8-bc79-68604ed88993_story.html?utm_term=.367baccf6385. Accessed on 16 April 2019.
Drucker E, Anderson K, Haemmig R, Heimer R, Small D, Walley A, Wood E, van Beek I. Treating addictions: harm reduction in clinical care and prevention. J Bioeth Inq. 2016;13(2):239–49. https://doi.org/10.1007/s11673-016-9720-6. Epub 26 Apr 2016.
Harm Reduction International. What is harm reduction? A position statement from Harm Reduction International. Available online at: https://www.hri.global/what-is-harm-reduction. Accessed 13 June 2018.
Harm reduction coalition. Principles of harm reduction. Available online at: http://harmreduction.org/about-us/principles-of-harm-reduction/. Accessed 13 June 2018.
United Nations Office on Drugs and Crime (2008). Reducing adverse health and social consequences of drug abuse: a comprehensive approach. Discussion paper. Available at: http://www.unodc.org/documents/prevention/Reducing-adverse-consequencesdrug-abuse.pdf.
Institute of Medicine (IOM). Crossing the quality chasm: a new health system for the 21st century. Washington, D.C.: National Academy Press; 2001.
Evans AC, White WL, Lamb R. The role of harm reduction in recovery-oriented systems of care: the Philadelphia experience. 2013. Available online at: http://www.williamwhitepapers.com/pr/Recovery%20and%20Harm%20Reduction%20In%20Philadelphia.pdf. Accessed 26 June 2018.
National Alliance of State and Territorial AIDS Directors (NASTAD) and the Urban Coalition for HIV/AIDS Prevention Services (UCHAPS). Syringe Services Program (SSP) Development and Implementation Guidelines for State and Local Health Departments. August 2012. Available online at: https://nasen.org/site_media/files/ssp-guidelines/SSPGuidelinesAugust2012.pdf. Accessed 13 July 2018.
Fernandes RM, Cary M, Duarte G, Jesus G, Alarcão J, Torre C, Costa S, Costa J, Carneiro V. Effectiveness of needle and syringe Programmes in people who inject drugs – an overview of systematic reviews. BMC Public Health. 2017;17:309.
Kidorf M, King VL, Peirce J, Kolodner K, Brooner RK. An observation of lower rates of drug use over time in community syringe exchangers. Am J Addict. 2013;22(3):271–6.
Hagan H, McGough JP, Thiede H, Hopkins S, Duchin J, Alexander ER. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abus Treat. 2000;19(3):247–52.
Potier C, Laprévote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014;145:48–68.
Wood E, Kerr T, Small W, Li K, Marsh DC, Montaner JS, Tyndall MW. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ. 2004;171(7):731–4.
Milloy M-JS, Kerr T, Tyndall M, Montaner J, Wood E. Estimated drug overdose deaths averted by North America’s first medically-supervised safer injection facility. PLoS One. 2008;3(10):e3351.
Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377(9775):1429–37.
Irwin A, Jozaghi E, Weir BW, Allen ST, Lindsay A, Sherman SG. Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility. Harm Reduct J. 2017;14(1):29.
Gaddis A, Kennedy MC, Nosova E, Milloy MJ, Hayashi K, Wood E, Kerr T. Use of on-site detoxification services co-located with a supervised injection facility. J Subst Abus Treat. 2017;82:1–6.
Siegler A, Huxley-Reicher Z, Maldjian L, Jordan R, Oliver C, Jakubowski A, Kunins HV. Naloxone use among overdose prevention trainees in New York City: a longitudinal cohort study. Drug Alcohol Depend. 2017;179:124–30.
Wheeler E, Jones TS, Gilbert MK, Davidson PJ, Centers for Disease Control and Prevention (CDC). Opioid overdose prevention programs providing naloxone to laypersons – United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(23):631–5.
Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, Ruiz S, Ozonoff A. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158(1):1–9.
Doe-Simkins M, Quinn E, Xuan Z, Sorensen-Alawad A, Hackman H, Ozonoff A, Walley AY. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health. 2014;14(1):297.
Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137–45.
Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, Robertson JR. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ. 2010;341:c3172.
Peles E, Schreiber S, Adelson M. Opiate-dependent patients on a waiting list for methadone maintenance treatment are at high risk for mortality until treatment entry. J Addict Med. 2013;7(3):177–82.
Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CB, Rouse CO, Callaman JM, O’Grady KE, Battjes RJ. A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006;63(1):102–9.
Sigmon SC, et al. Interim buprenorphine vs. waiting list for opioid dependence. N Engl J Med. 2016;375(25):2504–5.
Bhatraju EP, et al. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Addict Sci Clin Pract. 2017;12(1):7.
Bachhuber MA, Thompson C, Prybylowski A, Benitez J, Mazzella S, Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within prevention point Philadelphia, an urban syringe exchange program. Subst Abus. 2018;23:1–6.
Hall G, et al. Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals. J Subst Abus Treat. 2014;46(4):511–5. https://doi.org/10.1016/j.jsat.2013.11.002. Epub 2 Dec 2013.
Bassetti S, Battegay M. Staphylococcus aureus infections in injection drug users: risk factors and prevention strategies. Infection. 2004;32(3):163–9.
Degenhardt L, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–207. https://doi.org/10.1016/S2214-109X(17)30375-3. Epub 23 Oct 2017.
Levin MH, Weinstein RA, Nathan C, Selander RK, Ochman H, Kabins SA. Association of infection caused by Pseudomonas aeruginosa serotype O11 with intravenous abuse of pentazocine mixed with tripelennamine. J Clin Microbiol. 1984;20:758–62.
Podzamczer D, Ventin M, Sauca G, Fernandez-Viladrich P, Martin R, Gudiol F. Contaminated lemons as possible source of infection in heroin abusers with disseminated candidiasis. Eur J Clin Microbiol. 1986;5:477.
Swisher LA, Roberts JR, Glynn MJ. Needle licker’s osteomyelitis. Am J Emerg Med. 1994;12:343–6.
Murphy EL, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis. 2001;33(1):35–40. Epub 5 Jun 2001.
Mateu-Gelabert P, et al. The staying safe intervention: training people who inject drugs in strategies to avoid injection-related HCV and HIV infection. AIDS Educ Prev. 2014;26(2):144–57.
Callon C, Charles G, Alexander R, Small W, Kerr T. On the same level’: facilitators’ experiences running a drug user-led safer injecting education campaign. Harm Reduct J. 2013;10:4.
Wood RA, Wood E, Lai C, Tyndall MW, Montaner JS, Kerr T. Nurse-delivered safer injection education among a cohort of injection drug users: evidence from the evaluation of Vancouver’s supervised injection facility. Int J Drug Policy. 2008;19(3):183–8.
Ivsins A, Roth E, Nakamura N, Krajden M, Fischer B. Uptake, benefits of and barriers to safer crack use kit (SCUK) distribution programmes in Victoria, Canada--a qualitative exploration. Int J Drug Policy. 2011;22(4):292–300.
Leonard L, DeRubeis E, Pelude L, Medd E, Birkett N, Seto J. “I inject less as I have easier access to pipes”: injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed. Int J Drug Policy. 2008;19(3):255–64.
Rehm J, et al. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet. 2001;358:1417–23.
Van den Brink W, et al. Medical prescription of heroin to treatment resistant heroin addicts: two randomized controlled trials. BMJ. 2003;327:310–5.
Blanken P, Hendriks VM, Koeter MW, van Ree JM, van den Brink W. Craving and illicit heroin use among patients in heroin-assisted treatment. Drug Alcohol Depend. 2012;120(1–3):74–80.
Demaret I, Quertemont E, Litran G, Magoga C, Deblire C, Dubois N, De Roubaix J, Charlier C, Lemaître A, Ansseau M. Efficacy of heroin-assisted treatment in Belgium: a randomised controlled trial. Eur Addict Res. 2015;21(4):179–87.
Rehm J, Frick U, Hartwig C, Gutzwiller F, Gschwend P, Uchtenhagen A. Mortality in heroin-assisted treatment in Switzerland 1994-2000. Drug Alcohol Depend. 2005;79(2):137–43.
Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev. 2011;(12):CD003410.
Centers for Disease Control and Prevention (CDC). Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. MMWR Morb Mortal Wkly Rep. 2013;62(23):463–5.
McNeil R, Kerr T, Pauly B, Wood E, Small W. Advancing patient-centered care for structurally vulnerable drug-using populations: a qualitative study of the perspectives of people who use drugs regarding the potential integration of harm reduction interventions into hospitals. Addiction. 2016;111(4):685–94.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Wakeman, S.E. (2019). Harm Reduction Approaches for Opioid Use Disorder. In: Kelly, J., Wakeman, S. (eds) Treating Opioid Addiction. Current Clinical Psychiatry. Humana, Cham. https://doi.org/10.1007/978-3-030-16257-3_8
Download citation
DOI: https://doi.org/10.1007/978-3-030-16257-3_8
Published:
Publisher Name: Humana, Cham
Print ISBN: 978-3-030-16256-6
Online ISBN: 978-3-030-16257-3
eBook Packages: MedicineMedicine (R0)